X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (244) 244
index medicus (232) 232
humans (212) 212
female (174) 174
middle aged (146) 146
male (145) 145
aged (135) 135
adult (130) 130
neoplasms - drug therapy (106) 106
cancer (101) 101
pharmacology & pharmacy (88) 88
medicine & public health (68) 68
pharmacology/toxicology (66) 66
tumors (64) 64
pharmacokinetics (61) 61
aged, 80 and over (60) 60
dose-response relationship, drug (60) 60
antineoplastic agents - therapeutic use (58) 58
treatment outcome (58) 58
antineoplastic agents - adverse effects (56) 56
maximum tolerated dose (51) 51
research (49) 49
antineoplastic agents - administration & dosage (48) 48
antineoplastic agents - pharmacokinetics (48) 48
solid tumors (47) 47
neoplasms - pathology (45) 45
care and treatment (43) 43
article (42) 42
animals (38) 38
drug administration schedule (37) 37
clinical trials (36) 36
drug therapy (35) 35
chemotherapy (34) 34
pharmacology (34) 34
trial (34) 34
administration, oral (33) 33
therapy (33) 33
antimitotic agents (31) 31
antineoplastic agents (31) 31
antineoplastic combined chemotherapy protocols - therapeutic use (30) 30
complications and side effects (30) 30
dosage and administration (29) 29
neoplasms - metabolism (28) 28
toxicity (28) 28
antineoplastic combined chemotherapy protocols - adverse effects (27) 27
breast cancer (27) 27
patients (27) 27
mice (26) 26
safety (26) 26
breast neoplasms - drug therapy (23) 23
studies (23) 23
cell lung-cancer (22) 22
metastasis (22) 22
antineoplastic agents - pharmacology (21) 21
area under curve (21) 21
phase i (21) 21
young adult (21) 21
analysis (20) 20
cancer research (20) 20
breast-cancer (19) 19
cancer therapies (18) 18
cells (18) 18
expression (18) 18
efficacy (17) 17
neoplasm staging (17) 17
trastuzumab (17) 17
antineoplastic combined chemotherapy protocols - administration & dosage (16) 16
antitumor-activity (16) 16
half-life (16) 16
infusions, intravenous (16) 16
melanoma (16) 16
health aspects (15) 15
protein kinase inhibitors - therapeutic use (15) 15
survival (15) 15
activation (14) 14
mutations (14) 14
protein kinase inhibitors - adverse effects (14) 14
signal transduction - drug effects (14) 14
drug dosages (13) 13
medical research (13) 13
nausea (13) 13
neoplasm metastasis (13) 13
open-label (13) 13
time factors (13) 13
angiogenesis (12) 12
antibodies, monoclonal - administration & dosage (12) 12
antineoplastic agents - blood (12) 12
breast neoplasms - pathology (12) 12
pharmacodynamics (12) 12
tyrosine kinase inhibitor (12) 12
antibodies, monoclonal - adverse effects (11) 11
bevacizumab (11) 11
carcinoma, non-small-cell lung - drug therapy (11) 11
deoxycytidine - analogs & derivatives (11) 11
drug interactions (11) 11
fatigue (11) 11
inhibitor (11) 11
inhibitors (11) 11
lung neoplasms - drug therapy (11) 11
mutation (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Cancer Therapeutics, ISSN 1535-7163, 12/2017, Volume 16, Issue 12, pp. 2641 - 2644
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 04/2019, Volume 25, Issue 7, pp. 2049 - 2057
The 2018 Accelerating Anticancer Agent Development ( AAADV) Workshop assembled a panel of experts for an in-depth discussion session to present "Challenges... 
CELL LUNG-CANCER | BASKET TRIALS | PEMBROLIZUMAB | BIOMARKER | ONCOLOGY | THERAPIES | ACCELERATED APPROVAL | NIVOLUMAB | TUMORS | DOCETAXEL
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2018, Volume 24, Issue 16, pp. 3820 - 3828
Purpose: AZD1775 is a first-in-class Wee1 inhibitor with dual function as a DNA damage sensitizer and cytotoxic agent. A phase I study of AZD1775 for solid... 
DNA-DAMAGING AGENTS | EFFICACY | ONCOLOGY | WEE1 KINASE INHIBITOR | MITOTIC CATASTROPHE | P53-DEFICIENT TUMOR-CELLS | G CHECKPOINT | BLOOD-BRAIN-BARRIER | MK-1775 | TEMOZOLOMIDE
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. CT012 - CT012
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2017, Volume 35, Issue 5, pp. 669 - 669
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s10637-017-0479-3 
Medicine & Public Health | Pharmacology/Toxicology | Oncology | Solid tumors | Tumors
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 743 - 754
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, p. 4190
Therapeutic nanoparticles are designed to deliver their drug payloads through enhanced permeability and retention (EPR) in solid tumors. The extent of EPR and... 
Journal Article
Future oncology (London, England), 03/2018, Volume 14, Issue 7, p. 589
Trastuzumab emtansine is an antibody-drug conjugate comprised of the anti-HER2 monoclonal antibody trastuzumab linked to DM1 (emtansine), a potent cytotoxic... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2012, Volume 30, Issue 7, pp. 762 - 763
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 12, pp. 1164 - 1172
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.